Twist Bioscience Reports Second Quarter Fiscal 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Twist Bioscience Corporation (TWST) Misses Q2 EPS by 1c, Revenues Beat; Raises FY21 Revenues Guidance Above Consensus
May 6, 2021 5:15 PM EDTTwist Bioscience Corporation (NASDAQ: TWST) reported Q2 EPS of ($0.78), $0.01 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $31.2 million versus the consensus estimate of $28.32 million.
FISCAL 2021 SECOND QUARTER FINANCIAL RESULTS
Orders: Total orders received for the second quarter of fiscal 2021 were $41.7 million, compared to $24.6 million for the same period of fiscal 2020.Revenue: Total revenues were $31.2 million for the second quarter of fiscal 2021 compared to $19.3 million for the same period of fiscal 2020.Cost of Revenues: Cost of revenues for the second quarter of fiscal 2021 was $19.0 million... More